In 109 adults with CCUS or lower-risk myeloid malignancies, oral vitamin C 1000 mg/day for 12 months did not change median clonal growth rate vs placebo (p=.70). Serious adverse events were fewer (33% vs 57%); exploratory overall survival HR 0.35.
RCTn = 109
Mikkelsen et al. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial